Calypte Biomedical Completes First Sale of Aware(TM) HIV-1/2 OMT
Rapid Oral Fluid Test in India

PORTLAND, Ore., Feb 06, 2008 (BUSINESS WIRE) -- Calypte Biomedical
Corporation (OTCBB: CBMC), a developer, manufacturer and marketer of
HIV diagnostic tests, today announced the first sale of its Aware(TM:
109.89, +2.11, +1.95%) HIV-1/2 OMT rapid oral fluid test in India.
The tests were purchased by one of the paramilitary forces of the
Government of India.

Roger I. Gale, Calypte's President and Chief Executive Officer,
stated, "This sale marks a major milestone for us both as our first
sale in India and as our entry into the Indian governmental market.
Our Aware(TM: 109.89, +2.11, +1.95%) oral fluid test is ideally
suited for large institutions such as India's paramilitary forces
which need to protect the welfare of their workforces." Mr. Gale
continued, "We applaud the Government of India's ambitious plans to
combat HIV/AIDS. We believe that the safety and ease of use of non-
invasive tests such as our Aware(TM: 109.89, +2.11, +1.95%) HIV-1/2
OMT will be instrumental in containing costs and improving
efficiencies as India scales up its testing initiatives. Calypte's
Aware(TM: 109.89, +2.11, +1.95%) HIV-1/2 OMT test is the first and
currently only oral fluid test approved in India."

Sujata Mital, Director of Sumit Biosciences Pvt. Ltd., Calypte's
distributor in India, stated, "India's paramilitary forces have a
vested interest in guarding the health and welfare of their
personnel. These personnel are highly trained and make important
contributions to guarding India's security. Non-invasive testing will
help India's paramilitary organizations safeguard their commitment to
and investment in human capital. Further, the experience with non-
invasive testing gained by these organizations will concretely
demonstrate the advantages of oral fluid testing."

About India's HIV Program
India recently embarked on its Third National AIDS Control Program
(NACP-III) with the overall goal of halting and reversing its
HIV/AIDS epidemic. Since India's reported prevalence rate remains
well below 1%, the major focus of NACP-III will be on scaling up
prevention and control initiatives. According to The World Bank
Project Appraisal Document on NACP-III, India; dated March 22, 2007,
of the US $2.6 billion budgeted over five years for NACP-III, over US
$1.8 billion has been allocated to scaling up prevention efforts. One
of the major goals cited for NACP-III is increasing the number of
people tested from 3 million in 2006 to 22 million by 2011.

About Calypte Biomedical:
Calypte Biomedical Corporation (www.calypte.com) is a U.S.-based
healthcare company focused on the development and commercialization
of rapid testing products for sexually transmitted diseases such as
the Aware(TM: 109.89, +2.11, +1.95%) HIV-1/2 OMT test that are
suitable for use at the point of care and at home. Calypte believes
there is a significant need for rapid detection of such diseases
globally to control their proliferation, particularly in developing
countries, which lack the medical infrastructure to support
laboratory-based testing. Calypte believes that testing for HIV and
other sexually transmitted infectious diseases may make important
contributions to public health, and could increase the likelihood of
treating those with undetected HIV and other sexually transmitted
diseases.

SOURCE: Calypte Biomedical Corporation
Calypte Biomedical Corporation
Jerrold D. Dotson, 503-726-2227
VP-Finance, jdotson@...

http://www.foxbusiness.com/markets/industries/health-
care/article/calypte-biomedical-completes-sale-awaretm-hiv12f2-omt-
rapid-oral-fluid-test_467378_10.html